TWI679988B - 含有抗-介白素-４受體（ｉｌ-４ｒ）抗體之安定化配製物 - Google Patents

含有抗-介白素-４受體（ｉｌ-４ｒ）抗體之安定化配製物 Download PDF

Info

Publication number: TWI679988B
Authority: TW; Taiwan
Prior art keywords: antibody; formulation; pharmaceutical formulation; specific embodiment; months
Prior art date: 2010-10-06

Application number

TW105134483A

Other languages

English (en)

Chinese (zh)

Other versions

TW201716086A (zh

Inventor

丹尼爾狄克斯

Daniel Dix

湯曉林

Xiaolin Tang

Original Assignee

美商再生元醫藥公司

Regeneron Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-06

Filing date

2011-10-05

Publication date

2019-12-21

2011-10-05 Application filed by 美商再生元醫藥公司, Regeneron Pharmaceuticals, Inc. filed Critical 美商再生元醫藥公司

2017-05-16 Publication of TW201716086A publication Critical patent/TW201716086A/zh

2019-12-21 Application granted granted Critical

2019-12-21 Publication of TWI679988B publication Critical patent/TWI679988B/zh

Links

239000000203 mixture Substances 0.000 title abstract description 90
238000009472 formulation Methods 0.000 title abstract description 86
229940028885 interleukin-4 Drugs 0.000 title description 8
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 102
241000282414 Homo sapiens Species 0.000 claims abstract description 47
150000001413 amino acids Chemical class 0.000 claims abstract description 31
101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims abstract description 8
102000054663 human IL4R Human genes 0.000 claims abstract description 8
239000007788 liquid Substances 0.000 claims description 45
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 23
229920001213 Polysorbate 20 Polymers 0.000 claims description 22
229930006000 Sucrose Natural products 0.000 claims description 22
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 22
239000005720 sucrose Substances 0.000 claims description 22
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 21
229940068977 polysorbate 20 Drugs 0.000 claims description 21
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 20
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 16
239000004475 Arginine Substances 0.000 claims description 8
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
229920000136 polysorbate Polymers 0.000 claims description 8
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims description 8
229950008882 polysorbate Drugs 0.000 claims description 7
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
229920000053 polysorbate 80 Polymers 0.000 claims description 4
229940068968 polysorbate 80 Drugs 0.000 claims description 4
229940063675 spermine Drugs 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 2
238000003860 storage Methods 0.000 abstract description 37
230000027455 binding Effects 0.000 abstract description 26
239000002736 nonionic surfactant Substances 0.000 abstract description 3
150000001720 carbohydrates Chemical class 0.000 abstract description 2
238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 42
239000000872 buffer Substances 0.000 description 35
238000000034 method Methods 0.000 description 25
239000000427 antigen Substances 0.000 description 21
102000036639 antigens Human genes 0.000 description 21
108091007433 antigens Proteins 0.000 description 21
239000000243 solution Substances 0.000 description 21
239000006184 cosolvent Substances 0.000 description 19
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 18
239000011521 glass Substances 0.000 description 18
238000004007 reversed phase HPLC Methods 0.000 description 18
239000012634 fragment Substances 0.000 description 17
239000012760 heat stabilizer Substances 0.000 description 17
239000007853 buffer solution Substances 0.000 description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
239000002253 acid Substances 0.000 description 15
239000012669 liquid formulation Substances 0.000 description 15
235000001014 amino acid Nutrition 0.000 description 14
238000001542 size-exclusion chromatography Methods 0.000 description 14
229910052721 tungsten Inorganic materials 0.000 description 14
108090000623 proteins and genes Proteins 0.000 description 13
239000007858 starting material Substances 0.000 description 13
239000010937 tungsten Substances 0.000 description 13
WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 12
108010047041 Complementarity Determining Regions Proteins 0.000 description 11
229940024606 amino acid Drugs 0.000 description 11
230000000694 effects Effects 0.000 description 11
235000018102 proteins Nutrition 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
230000001225 therapeutic effect Effects 0.000 description 11
230000002378 acidificating effect Effects 0.000 description 9
201000010099 disease Diseases 0.000 description 9
239000000126 substance Substances 0.000 description 9
235000000346 sugar Nutrition 0.000 description 9
238000005341 cation exchange Methods 0.000 description 8
238000001802 infusion Methods 0.000 description 8
230000003287 optical effect Effects 0.000 description 8
239000000546 pharmaceutical excipient Substances 0.000 description 8
239000002904 solvent Substances 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 7
238000005277 cation exchange chromatography Methods 0.000 description 7
208000035475 disorder Diseases 0.000 description 7
230000008642 heat stress Effects 0.000 description 7
102000004388 Interleukin-4 Human genes 0.000 description 6
108090000978 Interleukin-4 Proteins 0.000 description 6
229920002508 Poloxamer 181 Polymers 0.000 description 6
239000008351 acetate buffer Substances 0.000 description 6
229960003121 arginine Drugs 0.000 description 6
235000009697 arginine Nutrition 0.000 description 6
230000015556 catabolic process Effects 0.000 description 6
238000006731 degradation reaction Methods 0.000 description 6
210000004602 germ cell Anatomy 0.000 description 6
229940085692 poloxamer 181 Drugs 0.000 description 6
125000000185 sucrose group Chemical group 0.000 description 6
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 5
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 5
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
108060003951 Immunoglobulin Proteins 0.000 description 4
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
-1 polyoxyethylene groups Polymers 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
230000000087 stabilizing effect Effects 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
150000005846 sugar alcohols Chemical class 0.000 description 4
KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 3
101100075829 Caenorhabditis elegans mab-3 gene Proteins 0.000 description 3
101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 3
229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 3
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000002776 aggregation Effects 0.000 description 3
238000004220 aggregation Methods 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
239000006172 buffering agent Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000007717 exclusion Effects 0.000 description 3
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
238000001182 laser chemical vapour deposition Methods 0.000 description 3
229920002521 macromolecule Polymers 0.000 description 3
ORMNNUPLFAPCFD-DVLYDCSHSA-M phenethicillin potassium Chemical compound [K+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C(C)OC1=CC=CC=C1 ORMNNUPLFAPCFD-DVLYDCSHSA-M 0.000 description 3
229920001993 poloxamer 188 Polymers 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
230000002265 prevention Effects 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
239000000047 product Substances 0.000 description 3
239000003017 thermal stabilizer Substances 0.000 description 3
KBDDIZRDKLGWGW-UHFFFAOYSA-N 3-[4-(3-aminopropylamino)butylamino]propylazanium;chloride Chemical group [Cl-].NCCCNCCCCNCCC[NH3+] KBDDIZRDKLGWGW-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
AIRYAONNMGRCGJ-FHFVDXKLSA-N CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC AIRYAONNMGRCGJ-FHFVDXKLSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
206010012438 Dermatitis atopic Diseases 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
229920002556 Polyethylene Glycol 300 Polymers 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
201000009961 allergic asthma Diseases 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
201000008937 atopic dermatitis Diseases 0.000 description 2
229940090047 auto-injector Drugs 0.000 description 2
230000008827 biological function Effects 0.000 description 2
230000006652 catabolic pathway Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000006240 deamidation Effects 0.000 description 2
230000005484 gravity Effects 0.000 description 2
229960001340 histamine Drugs 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 2
229920000831 ionic polymer Polymers 0.000 description 2
239000006193 liquid solution Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229940050929 polyethylene glycol 3350 Drugs 0.000 description 2
230000008569 process Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
241000894007 species Species 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
230000035882 stress Effects 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
206010010744 Conjunctivitis allergic Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010065920 Insulin Lispro Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001219 Polysorbate 40 Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
229920002642 Polysorbate 65 Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
241000219492 Quercus Species 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
240000000111 Saccharum officinarum Species 0.000 description 1
235000007201 Saccharum officinarum Nutrition 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
238000011481 absorbance measurement Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
230000004523 agglutinating effect Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
230000004075 alteration Effects 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000024998 atopic conjunctivitis Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
102000003675 cytokine receptors Human genes 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
125000002228 disulfide group Chemical group 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
229940015979 epipen Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
229940038661 humalog Drugs 0.000 description 1
102000055229 human IL4 Human genes 0.000 description 1
229940048921 humira Drugs 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000010355 oscillation Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229940044519 poloxamer 188 Drugs 0.000 description 1
229940044476 poloxamer 407 Drugs 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229940101027 polysorbate 40 Drugs 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
229940099511 polysorbate 65 Drugs 0.000 description 1
229940113171 polysorbate 85 Drugs 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229940071643 prefilled syringe Drugs 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
QHGVXILFMXYDRS-UHFFFAOYSA-N pyraclofos Chemical compound C1=C(OP(=O)(OCC)SCCC)C=NN1C1=CC=C(Cl)C=C1 QHGVXILFMXYDRS-UHFFFAOYSA-N 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000009774 resonance method Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000000646 scanning calorimetry Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000008646 thermal stress Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TW105134483A 2010-10-06 2011-10-05 含有抗-介白素-４受體（ｉｌ-４ｒ）抗體之安定化配製物 TWI679988B (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US39028310P	2010-10-06	2010-10-06
US61/390,283		2010-10-06

Publications (2)

Publication Number	Publication Date
TW201716086A TW201716086A (zh)	2017-05-16
TWI679988B true TWI679988B (zh)	2019-12-21

Family

ID=45995014

Family Applications (7)

Application Number	Title	Priority Date	Filing Date
TW105134483A TWI679988B (zh)	2010-10-06	2011-10-05	含有抗-介白素-４受體（ｉｌ-４ｒ）抗體之安定化配製物
TW104123984A TWI568445B (zh)	2010-10-06	2011-10-05	含有液態醫藥配製物之預填充針筒
TW111138434A TWI856388B (zh)	2010-10-06	2011-10-05	含有抗-介白素-4受體(il-4r)抗體之安定化配製物
TW109107375A TWI718890B (zh)	2010-10-06	2011-10-05	含有抗-介白素-4受體(il-4r)抗體之安定化配製物
TW109131629A TWI782325B (zh)	2010-10-06	2011-10-05	含有抗-介白素-4受體(il-4r)抗體之安定化配製物
TW108111631A TWI690329B (zh)	2010-10-06	2011-10-05	含有抗-介白素-４受體（ｉｌ-４ｒ）抗體之安定化配製物
TW100135992A TWI498121B (zh)	2010-10-06	2011-10-05	含有抗－介白素－４受體（ｉｌ－４ｒ）抗體之安定化配製物

Family Applications After (6)

Application Number	Title	Priority Date	Filing Date
TW104123984A TWI568445B (zh)	2010-10-06	2011-10-05	含有液態醫藥配製物之預填充針筒
TW111138434A TWI856388B (zh)	2010-10-06	2011-10-05	含有抗-介白素-4受體(il-4r)抗體之安定化配製物
TW109107375A TWI718890B (zh)	2010-10-06	2011-10-05	含有抗-介白素-4受體(il-4r)抗體之安定化配製物
TW109131629A TWI782325B (zh)	2010-10-06	2011-10-05	含有抗-介白素-4受體(il-4r)抗體之安定化配製物
TW108111631A TWI690329B (zh)	2010-10-06	2011-10-05	含有抗-介白素-４受體（ｉｌ-４ｒ）抗體之安定化配製物
TW100135992A TWI498121B (zh)	2010-10-06	2011-10-05	含有抗－介白素－４受體（ｉｌ－４ｒ）抗體之安定化配製物

Country Status (13)

Country	Link
AR (1)	AR083338A1 (sr)
DK (2)	DK3354280T3 (sr)
ES (2)	ES2820246T3 (sr)
HR (1)	HRP20181822T1 (sr)
HU (1)	HUE052089T2 (sr)
LT (1)	LT2624865T (sr)
PT (1)	PT3354280T (sr)
RS (1)	RS57850B1 (sr)
SI (1)	SI2624865T1 (sr)
SM (1)	SMT201800488T1 (sr)
TW (7)	TWI679988B (sr)
UA (1)	UA111731C2 (sr)
UY (1)	UY33652A (sr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9574004B2 (en)	2012-08-21	2017-02-21	Sanofi Biotechnology	Methods for treating or preventing asthma by administering an IL-4R antagonist
TWI707694B (zh) *	2013-06-21	2020-10-21	法商賽諾菲生物技術公司	Ｉｌ-４ｒ拮抗劑用於製造治療鼻息肉症的藥物之用途
CN111437387B (zh) *	2013-06-21	2024-10-01	赛诺菲生物技术公司	通过施用il-4r拮抗剂治疗鼻息肉症的方法
AU2015346150B2 (en)	2014-11-14	2021-08-19	Regeneron Pharmaceuticals, Inc.	Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
CA3079946A1 (en)	2017-10-30	2019-05-09	Sanofi Biotechnology	Methods for treating or preventing asthma by administering an il-4r antagonist
BR112022000740A2 (pt)	2019-07-16	2022-07-05	Sanofi Biotechnology	Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010053751A1 (en) *	2008-10-29	2010-05-14	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human il-4 receptor
WO2010102241A1 (en) *	2009-03-06	2010-09-10	Genentech, Inc.	Antibody formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2332082B1 (es) *	2008-07-24	2010-10-26	Consejo Superior De Investigaciones Cientificas (Csic) 45%	Sistema de alineacion de patrones en un sustrato mediante litografia por estencil.
KR101593726B1 (ko) *	2008-09-10	2016-02-18	니혼 엑스란 고교 (주)	가교 아크릴레이트계 섬유 및 이의 제조방법

2011
- 2011-05-10 UA UAA201305598A patent/UA111731C2/uk unknown
- 2011-10-03 AR ARP110103663 patent/AR083338A1/es not_active Application Discontinuation
- 2011-10-05 TW TW105134483A patent/TWI679988B/zh active
- 2011-10-05 TW TW104123984A patent/TWI568445B/zh active
- 2011-10-05 TW TW111138434A patent/TWI856388B/zh active
- 2011-10-05 SI SI201131568T patent/SI2624865T1/sl unknown
- 2011-10-05 HU HUE18161288A patent/HUE052089T2/hu unknown
- 2011-10-05 LT LTEP11770625.9T patent/LT2624865T/lt unknown
- 2011-10-05 PT PT181612888T patent/PT3354280T/pt unknown
- 2011-10-05 RS RS20181308A patent/RS57850B1/sr unknown
- 2011-10-05 HR HRP20181822TT patent/HRP20181822T1/hr unknown
- 2011-10-05 TW TW109107375A patent/TWI718890B/zh active
- 2011-10-05 TW TW109131629A patent/TWI782325B/zh active
- 2011-10-05 DK DK18161288.8T patent/DK3354280T3/da active
- 2011-10-05 ES ES18161288T patent/ES2820246T3/es active Active
- 2011-10-05 TW TW108111631A patent/TWI690329B/zh active
- 2011-10-05 TW TW100135992A patent/TWI498121B/zh active
- 2011-10-05 ES ES11770625.9T patent/ES2687813T3/es active Active
- 2011-10-05 DK DK11770625.9T patent/DK2624865T3/en active
- 2011-10-05 SM SM20180488T patent/SMT201800488T1/it unknown
- 2011-10-06 UY UY33652A patent/UY33652A/es unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010053751A1 (en) *	2008-10-29	2010-05-14	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human il-4 receptor
WO2010102241A1 (en) *	2009-03-06	2010-09-10	Genentech, Inc.	Antibody formulation

Also Published As

Publication number	Publication date
HK1258305A1 (en)	2019-11-08
AR083338A1 (es)	2013-02-21
UY33652A (es)	2012-04-30
UA111731C2 (uk)	2016-06-10
LT2624865T (lt)	2018-10-25
HUE052089T2 (hu)	2021-04-28
TW201542229A (zh)	2015-11-16
TW201221141A (en)	2012-06-01
RS57850B1 (sr)	2018-12-31
TW202102262A (zh)	2021-01-16
SMT201800488T1 (it)	2018-11-09
TW202320851A (zh)	2023-06-01
DK2624865T3 (en)	2018-10-22
TWI718890B (zh)	2021-02-11
PT3354280T (pt)	2020-09-01
DK3354280T3 (da)	2020-09-28
TWI568445B (zh)	2017-02-01
ES2687813T3 (es)	2018-10-29
TW202026011A (zh)	2020-07-16
TWI782325B (zh)	2022-11-01
TW201716086A (zh)	2017-05-16
ES2820246T3 (es)	2021-04-20
TWI498121B (zh)	2015-09-01
HRP20181822T1 (hr)	2018-12-28
TWI690329B (zh)	2020-04-11
TWI856388B (zh)	2024-09-21
SI2624865T1 (sl)	2018-10-30
TW201924718A (zh)	2019-07-01

Publication	Publication Date	Title
US11926670B2 (en)	2024-03-12	Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
TWI679988B (zh)	2019-12-21	含有抗-介白素-４受體（ｉｌ-４ｒ）抗體之安定化配製物
HK40039744A (en)	2021-07-23	Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
HK1232793B (zh)	2021-11-26	含有抗白介素-4 受体(il-4r)的抗体的稳定制剂